Moderna’s combination Covid, flu vaccine is more effective than existing shots in late-stage trial

  • Moderna said its combination vaccine targeting Covid and the flu was more effective than existing standalone shots for those viruses in a late-stage trial.
  • The biotech company is the first to release positive phase three data on a Covid and flu combination shot, giving it a potential lead over rivals Pfizer and Novavax.
  • Moderna plans to file for regulatory approval for its combination jab this summer in the U.S. and hopes it can enter the market in 2025, said the company’s CEO Stephane Bancel.